Apr 23, 2014 ... Gilead (GILD) posted blockbuster sales for Sovaldi, outpacing ... Earnings
Roundup: What You Need to Know About Gilead's Blockbuster Quarter. Gilead ...
Olysio's sales totaled $350 million in the first quarter as the drug was ...
Oct 23, 2015 ... Gilead's earnings track record has been pretty good – last quarter, the company
... Gilead's blockbuster hepatitis C virus (HCV) treatments, Sovaldi and Harvoni,
are ... Harvoni should benefit from reimbursement in several European countries.
... Today, you can download 7 Best Stocks for the Next 30 Days.
WASHINGTON (AP) - Gilead Science Inc.'s earnings tumbled more than 17
percent in the first quarter as steeper discounts and rebates on its blockbuster
hepatitis C drugs cut ... "This was a weak quarter for Gilead, in our view, as sales
for hepatitis C ...
3 days ago ... Quotes you view appear here for quick access. ... The Zacks Analyst Blog
Highlights: Biogen, Sarepta, Catalyst Pharmaceuticals, AbbVie and Gilead ...
Biotech Stock Roundup. Biogen (BIIB) kick-started the earnings season for the
biotech sector ... Biogen's first-quarter results were mixed with the company ...
If you have a health policy haiku to share, please Contact Us and let us know if
you ... they would be eligible for Medicaid should soon have access to health
care, .... Aetna's first-quarter earnings slid nearly 7 percent as enrollment dipped,
but ... The drugmaker Gilead Sciences has seen its fortunes buoyed by its
Oct 1, 2014 ... News Roundup, October 2014: Walgreens, Cardinal Health, ... Yesterday, Gilead
Sciences reported another blockbuster quarter for Sovaldi sales. ... Based on the
chart below, I think you'll agree that Sovaldi is the most legendary of them all. ...
should—but probably won't—mute critics of preferred networks.
Apr 21, 2016 ... Welcome to our European Regulatory Roundup, our weekly ... If successful, the
trial could lead to PRAC running its first public hearing in the fourth quarter of
2016. ... hepatitis C drugs including Gilead Sciences' Sovaldi and Harvoni. ... is
required to run high-quality clinical trials in pediatric populations.
Mar 18, 2016 ... MannKind reported fourth quarter earnings on Tuesday. ... hopes pinned on
Afrezza becoming the next blockbuster drug as the first inhable insulin for adults
with diabetes, but the drug failed to bring in meaningful revenue and gain traction
... Biotech Beat: Analysts Weigh In On Gilead Sciences, Inc. (GILD), ...
Aug 19, 2015 ... Wear comfortable shoes, because it's a lot easier to stand and listen to the
concert — and sit in the sand, if you need to — than it is to drag ...
According to a new patent, It has a tiny display and a camera that you can control
by blinking your eye ..... Electric car buying guide: Everything you need to know.